{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Confirmed Partial Response (PR)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Confirmed Complete Response (CR)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"19"}],"units":"Participants"}],"description":"Tumor response is defined as the total number of eligible patients whose disease has a complete or partial response to GW786034 according to the RECIST criteria. A confirmed response is defined as a CR or PR and is documented on 2 consecutive evaluations.","groups":[{"description":"Patients receive oral pazopanib hydrochloride once daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Treatment (Enzyme Inhibitor Therapy)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Documented on 2 consecutive evaluations 8 weeks apart from the start of the treatment until disease progression/recurrence, assessed up to 1 year","title":"Confirmed Tumor Response (CR and PR)","type":"SECONDARY","unitOfMeasure":"participants"}